Clinical Nephrology – Epidemiology – Clinical Trials
Kidney International (2004) 66, 2010–2016; doi:10.1111/j.1523-1755.2004.00972.x
Survival following parathyroidectomy among United States dialysis patients
BRYAN KESTENBAUM, DENNIS L ANDRESS, STEPHEN M SCHWARTZ, DANIEL L GILLEN, STEPHEN L SELIGER, PARESH R JADAV, DONALD J SHERRARD and CATHERINE STEHMAN-BREEN
Division of Nephrology, University of Washington, Veterans' Affairs Puget Sound Health Care System, Seattle, Washington; Department of Epidemiology, University of Washington, Cardiovascular Health Research Unit, Seattle, Washington; Fred Hutchinson Cancer Research Center, Program in Epidemiology, Seattle, Washington; Department of Health Studies, University of Chicago, Chicago, Illinois; Division of Nephrology, University of Washington, Seattle, Washington; and Amgen, Incorporated, Thousand Oaks, California
Correspondence: Bryan Kestenbaum, M.D., MS, Veterans' Affairs Puget Sound Health Care System, Division of Nephrology, Mail Stop 111A, 1660 South Columbian Way, Seattle, WA 98108. E-mail:brk@u.washington.edu
Received 12 March 2004; Revised 18 May 2004; Accepted 27 May 2004.
Abstract
Survival following parathyroidectomy among United States dialysis patients.
Background
Secondary hyperparathyroidism (SHPTH) is highly prevalent among persons with end-stage renal disease (ESRD). SHPTH has been linked to uremic bone disease, vascular calcification, and a higher risk of death. Parathyroidectomy (PTX) can dramatically reduce parathyroid hormone (PTH) and phosphate levels; however, the relationship between PTX and survival is not known.
Methods
We conducted an observational matched cohort study utilizing data from the United States Renal Database System (USRDS) in which 4558 patients undergoing a first PTX while on hemodialysis or peritoneal dialysis were individually matched by age, race, gender, cause of ESRD, dialysis duration, prior transplantation status, and dialysis modality to 4558 control patients who did not undergo PTX. Patients were followed from the date of PTX until they died or were lost to follow-up.
Results
The 30-day postoperative mortality rate following PTX was 3.1%. Long-term relative risks of death among patients undergoing PTX were estimated to be 10% to 15% lower than those of matched control patients not undergoing surgery. Survival curves between the 2 groups crossed 587 days following PTX. Median survival was 53.4 months (95% CI: 51.2–56.4) in the PTX group, and 46.8 months (95% CI: 44.7–48.9) in the control group.
Conclusion
PTX was associated with higher short-term, and lower long-term, mortality rates among U.S. patients receiving chronic dialysis. Measures to attenuate SHPTH may play an important role in reducing mortality among patients with end-stage renal disease.
Keywords:
parathyroidectomy, parathyroid hormone, hyperparathyroidism, mortality, dialysis
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
Cardiovascular disease in children with CKD or ESRD
Nature Reviews Nephrology Review (01 Apr 2009)
RESEARCH
Parathyroidectomy rates among United States dialysis patients: 1990?1999 1
Kidney International Original Article
Risk factors and mortality associated with calciphylaxis in end-stage renal disease
Kidney International Original Article
Patients with Fabry disease on dialysis in the United States
Kidney International Original Article
Kidney International Original Article
